FONTANA 更新:叶酸受体靶向 ADC 在卵巢癌(含低/阴性表达)中展现抗肿瘤活性
Novel ADC Could Expand Treatment Options in Ovarian Cancer
MD Anderson 的 Funda Meric-Bernstam 在 ESMO 围绕 FONTANA 试验更新的独家采访中介绍,156 例经治卵巢癌患者中,叶酸受体高表达组客观缓解率 61.7%,低表达组 57%,超弱/阴性组 48%,且缓解持续;该药为探索中的拓扑异构酶类抗体偶联药物,目前仍在临床开发阶段。
FONTANA 更新数据展示在叶酸受体α低或阴性卵巢癌患者中仍具活性,可能扩大受益人群范围。
— Torvutatug samrotecan may benefit patients across folate receptor alpha expression levels
by Gregory Laub, Senior Director, Video, MedPage Today
November 18, 2026 • 3 min read
Updated results from the FONTANA trial presented at the annual European Society for Medical Oncology congress showed promising activity with the investigational antibody-drug conjugate (ADC) torvutatug samrotecan (torvu-sam) in patients with previously treated ovarian cancer, including those with low or absent folate receptor alpha expression.
In this exclusive MedPage Today video, Funda Meric-Bernstam, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses the findings and how torvu-sam could expand treatment options for a broader patient population, including its potential role alongside existing therapies and in future treatment settings.
Following is a transcript of her remarks:
FONTANA is looking at torvu-sam, which is a folate receptor antibody-drug conjugate. This is an antibody-drug conjugate that targets folate receptor and has a topoisomerase payload. This trial had presented at ESMO 2025 where the dose escalation had been shared, and this was updated data in that we had further follow-up on our dose optimization, and we'd also included a cohort of patients that had ultra-low or null expression of folate receptor. So these were results from 156 patients that had been previously treated and now getting this antibody-drug conjugate.
The class of topoisomerase ADCs I think are really emerging as an exciting therapeutic opportunity. And we were pleased to see the activity in the folate receptor expression-high cohort where the objective response rate was 61.7%. But also we enrolled patients that had folate receptor expression low, and in that patient population, the response rate was 57%. We also enrolled a group of patients that had shorter follow-up, but the objective response rate in the folate receptor expression ultra-low or null was 48%.
So overall, this was also notable that these responses were quite durable. And we reported in the folate receptor-high group, their durability was 10.2 months, with the folate receptor-low group being 8.3 months. So overall the PFS [progression-free survival] in the high group was 9.7 months and the low was 7.6 months. Taken together to suggest that really this is an active agent that has no new safety signals, adverse events consistent with the topoisomerase ADC mechanism of action.
These are different-mechanism-of-action ADCs. Mirvetuximab [soravtansine (Elahere)], of course, has a different safety profile as well, but notably patients need to have folate receptor expression tested and they need to have 75% tumor cell positivity for that monotherapy activity. So here, the fact that we saw activity in the low cohort, which had 25% of the tumor cells positive, as well as the ultra-low/null cohort, that really makes it a lot more promising because feasibly we could offer this therapy even without testing and a lot larger patient population will be able to benefit from this agent.
Currently, ongoing clinical trials are looking at torvu-sam in comparison with mirvetuximab in patients that are fully receptor-high, also comparing torvu-sam in patients... in fully super-low with standard chemotherapy, as well as looking at torvu-sam in the maintenance setting.
This is a really exciting time. We're learning more about how we can better target cell surface antigens, and I think topoisomerase inhibitors really have a great opportunity to be impactful in a much larger patient population.
来源:MedPage Today · medpagetoday.com